|
|
 |
|
Management Biographies |
|
|
 |
|
|
FRED HASSAN
Chairman of the Board and Chief Executive Officer
Schering-Plough Corporation
Kenilworth, New Jersey
Fred Hassan is chairman of the board and chief executive officer of Schering-Plough Corporation.
Prior to joining Schering-Plough in April 2003 and assuming his current position,
Hassan was chairman and chief executive officer of Pharmacia Corporation.
He joined the former Pharmacia & Upjohn in May 1997 as chief executive officer
and was elected to the Board of Directors. In February 2001, Hassan was named chairman
of the Board of Pharmacia, the company created through the merger of the former Monsanto
and Pharmacia & Upjohn companies.
Previously, Hassan was executive vice president of Wyeth, formerly known as
American Home Products, with responsibility for its pharmaceutical and medical
products business. He was elected to Wyeth's Board of Directors in 1995. Earlier
in his career, Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and
headed its U.S. pharmaceuticals business.
Hassan received a B.S. degree in chemical engineering from the Imperial College of
Science and Technology at the University of London and an M.B.A. from Harvard Business School.
Hassan is the past chairman of the Board of Directors of the Pharmaceutical Research
and Manufacturers of America (PhRMA) and is the immediate past chairman of the HealthCare
Institute of New Jersey. He is currently president of the International Federation of
Pharmaceutical Manufacturers Associations. In addition, he serves on the Board of Directors
of Avon Products, Inc.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
